Vitrolife Group (VITR) Q2 2024 earnings summary

Executive summary

• Q2 2024 net sales reached SEK 941 million, up 4% year-over-year in local currencies, with strong Technologies growth and improved margins.

• Gross margin increased to 59.9% (up from 55.8%), and EBITDA margin reached 34.7% (up from 32.4%), driven by favorable product mix and operational efficiencies.

• Net income rose to SEK 143 million, with earnings per share at SEK 1.06, both up from the prior year.

• Acquisition of eFertility completed, supporting digitalisation, automation, and platform integration in IVF clinic management.

• No significant events occurred after the reporting period.

Financial highlights

• Sales: SEK 941 million, up 4% year-over-year in local currency.

• Gross margin: 59.9% (up from 55.8% in Q2 2023); adjusted gross margin: 64.5% (61.0%).

• EBITDA: SEK 327 million, margin 34.7% (up from SEK 293 million and 32.4%).

• Net income: SEK 143 million (SEK 106 million in Q2 2023), net income margin 15.3%.

• Operating cash flow: SEK 236 million (SEK 211 million in Q2 2023).

Outlook and guidance

• Strategic focus on increasing market share in the US, China, and key regions, with continued investment in commercial capabilities and operational excellence.

• Expectation of improved performance in disposable devices in H2 due to phasing.

• Gross margin at ~60% seen as challenging to sustain, with some dilution possible from genomic kits.

• IVF cycles expected to grow globally by 5-7% annually, driven by demographic trends and supportive policies.

• Company aims to accelerate growth in Time Lapse, eWitness, and genetic testing sales.